Combination of Novel Therapies for CKD Comorbid Depression

Major Depressive Disorder Clinical Trial

— CONCORD  

Official title:

Combination of Novel Therapies for CKD Comorbid Depression (CONCORD)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04422652
• Other study ID #: STU-2020-0046
• Secondary ID: R01DK124379
• Status: Recruiting
• Phase: Phase 2
• Start date: September 24, 2020
• Est. completion date: April 1, 2026

Study information

• Verified date: August 2023
• Source: University of Texas Southwestern Medical Center
• Contact: Meredith McAdams, MD
• Phone: 214-645-5418
• Email: Meredith.McAdams[@]UTSouthwestern.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The overall goal of the study is to determine if treatment of a Major Depressive Disorder (MDD) improves the outcomes of patients with chronic kidney disease (CKD). We showed that MDD is present in 25% of CKD patients and independently associated with progression to End-Stage Kidney Disease, hospitalization, and death. Depression is also associated with lower quality of life (QOL), fatigue, poor sleep, and non-adherence to diet and medications. However, evidence for efficacy and tolerability of commonly-used antidepressant medications or nonpharmacologic treatments are limited in CKD patients. Our group was the first to conduct a double-blind randomized controlled trial for MDD treatment in 201 patients with non-dialysis CKD, and showed that sertraline, a commonly used selective serotonin reuptake inhibitor (SSRI), was no more efficacious than placebo for improving depressive symptoms. It becomes imperative to test novel strategies to treat MDD in CKD. We propose to compare with a control group, the efficacy and tolerability of two novel treatment strategies - (1) Behavioral Activation Teletherapy (BAT) for 16 weeks, with the addition of bupropion, a non-SSRI antidepressant, at 8 weeks for patients whose depression has not remitted (non-remitters); and (2) bupropion for 16 weeks, with the addition of BAT at 8 weeks for non-remitters. In Aim 1, we will investigate the efficacy and tolerability of these 2 strategies vs. control for improvement in a primary endpoint of depressive symptoms in 201 patients (67 per group) with non-dialysis CKD stages 3b-5 and MDD at 2 sites, randomized 1:1:1 to either strategy or a control group of Clinical Management plus placebo. We hypothesize that either approach vs. control will result in a minimal clinically important difference of 2 points improvement in depressive symptoms, as ascertained blindly by the Quick Inventory of Depressive Symptomatology. In Aim 2 we will investigate the efficacy and tolerability of 8 weeks of (1) single-blind BAT plus placebo or (2) double-blind bupropion plus Clinical Management vs. control for improvement in depressive symptoms. In Aim 3, we will compare the efficacy of these 2 treatments strategies vs. control for improvement in CKD patient-centered outcomes including a. adherence to medications and healthcare visits; b. fatigue; c. sleep; and d. overall functioning. A clinical trial is urgently needed to address the evidence gap that exists for MDD treatment in CKD patients.

Description:

Aim 1. Compare the efficacy and tolerability of two 16-week strategies vs. control for treatment of CKD patients with MDD starting with (1) BAT or (2) bupropion, each augmented to a combination of both in non-remitters. Primary hypothesis: Treatment with either strategy will improve depression (primary endpoint) and be tolerable.

Patients with non-dialysis stages 3b-5 CKD and MDD (N=201) will be randomized 1:1:1 to 16 weeks of:

Strategy 1: Single-blind BAT plus placebo, augmented in non-remitters at 8 weeks with single-blind bupropion; Strategy 2: Double-blind bupropion plus single-blind Clinical Management (CM) attention control, augmented in non-remitters at 8 weeks with single-blind BAT; Control: CM attention control plus placebo. There will be >80% power to detect a minimal clinically important difference (MCID) of 2 points on the Quick Inventory of Depressive Symptomatology between each intervention and control, assuming a 14% attrition rate.

Exploratory aim (a): Explore if remote access to therapy via internet vs. travel to clinic affects treatment efficacy.

Aim 2. Investigate efficacy and tolerability of 8 weeks (Phase 1) of (1) BAT plus placebo or (2) bupropion plus CM, vs. control, for improvement in depression. Secondary hypothesis: Treatment with 8 weeks of BAT or bupropion will improve depression. There will be 80% power to detect a MCID of 2 points between each arm and control, assuming 10% attrition.

Exploratory aims:

(a) Investigate whether patient preference for BAT vs. drug affects treatment efficacy; (b) compare efficacy of each combination in Phase 2 with control; (c) compare change from baseline in plasma C-reactive protein in drug vs. BAT or control arms.

Aim 3. Investigate the efficacy of these two 16-week treatment strategies vs. control for improvement in CKD patient-centered outcomes including: (a) adherence to medications and healthcare visits; (b) fatigue; (c) sleep; (d) overall functioning. Secondary hypothesis: Treatment with either strategy will result in clinically meaningful improvements in adherence, fatigue, sleep and overall functioning in patients with CKD.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 201
• Est. completion date: April 1, 2026
• Est. primary completion date: April 1, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Male or female adults aged 18 years or greater. There will be no upper age limit.

2. Presence of CKD stages 3b, 4 or non-dialysis stage 5, with an estimated glomerular filtration rate (GFR) of <45 mL/min/1.73 m2 for a period of at least 3 months, as defined by the National Kidney Foundation and determined using the four-variable Modification of Diet for Renal Diseases Study formula.

3. Presence of a current Major Depressive Disorder (MDD) based on MINI DSM IV-based criteria

4. Quick Inventory of Depressive Symptomatology-Self-report (QIDS-SR) score of =11 at enrollment and =11 on QIDS-Clinician Rated (QIDS-C) at randomization.

5. Able to understand and sign informed consent after the nature of the study has been fully explained

6. Kidney transplant patients that are at least 6 month post-transplantation (3 months post-transplant, with at least another 3 months to confirm eGFR <45)

Exclusion Criteria:

1. Unable to understand or give informed consent.

2. Unwilling or unable to participate in the protocol or comply with any of its components

3. Receiving chronic dialysis

4. Significant hepatic dysfunction or liver enzyme abnormalities 3 times or greater than the upper limit of normal

5. Terminal chronic obstructive pulmonary disease or cancer

6. Presence of seizure disorder

7. Current use of class I anti-arrhythmic medications (such as 1C propafenone and flecanide), pimozide, MAO inhibitors, reserpine, guanethidine, cimetidine, or methyldopa; tri-cyclic anti-depressants, neuroleptics, or anti-convulsants

8. Use of serotonergic drugs or supplements such as triptans, tramadol, linezolid, tryptophan, and St. John's Wort.

9. Use of medications known to cause QT prolongation on EKG

10. Ongoing use of antidepressant medications for depression treatment

11. Past treatment failure on bupropion

12. Initiation of depression-focused psychotherapy in the 3 months prior to study entry

13. Active alcohol or substance abuse or dependence that requires acute detoxification at study entry

14. Present or past psychosis or Bipolar I or II disorder

15. Dementia or a Mini-Mental State Examination score <23

16. Active suicidal intent

17. Pregnancy, lactation, or women of childbearing potential not willing to use adequate contraception

Related Conditions & MeSH terms

• Chronic Kidney Diseases
• Depressive Disorder
• Depressive Disorder, Major
• Kidney Diseases
• Major Depressive Disorder
• Renal Insufficiency, Chronic

Intervention

Drug:
• Bupropion
Bupropion is an anti-depressant medication.

Behavioral:
• Behavioral activation therapy
Brief behavioral activation treatments administered via video tele-conferencing.

Drug:
• Placebo
Double-blind placebo.

Other:
• Clinical Management
Clinical management will serve as the attention control for the Behavioral Activation Therapy intervention.

Locations

Country	Name	City	State
United States	Parkland Health and Hospital System	Dallas	Texas
United States	UT Southwestern and Affiliates	Dallas	Texas
United States	University of Washington	Seattle	Washington
United States	Stony Brook University Medical Center	Stony Brook	New York

Sponsors (4)

Lead Sponsor	Collaborator
University of Texas Southwestern Medical Center	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Stony Brook University, University of Washington

Country where clinical trial is conducted

United States, 

References & Publications (1)

Hedayati SS, Gregg LP, Carmody T, Jain N, Toups M, Rush AJ, Toto RD, Trivedi MH. Effect of Sertraline on Depressive Symptoms in Patients With Chronic Kidney Disease Without Dialysis Dependence: The CAST Randomized Clinical Trial. JAMA. 2017 Nov 21;318(19):1876-1890. doi: 10.1001/jama.2017.17131. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Quick Inventory of Depressive Symptomatology-Clinician Rated scale (QIDS-C)	Assess the change from baseline in the QIDS-C total score in each of the intervention arms vs. the control arm. The score on the QIDS-C ranges from 0-27, with higher scores indicating more severe depressive symptoms.	Assessed at baseline and weeks 4, 6, 8, 12, and 16
Secondary	Serious adverse events	Pre-specified serious adverse events include death, hospitalization, renal replacement therapy (dialysis or kidney transplantation), and acute suicidal intent.	Assessed at weeks 4, 6, 8, 12, and 16.
Secondary	Quick Inventory of Depressive Symptomatology-Clinician Rated scale (QIDS-C)	Assess the change from baseline in the QIDS-C total score in each of the intervention arms vs. the control arm during the first 8 weeks of the study when participants in the treatment arms will be receiving monotherapy with BAT or bupropion.	Assessed at baseline and weeks 4, 6, and 8.
Secondary	Serious adverse events with monotherapy	Pre-specified serious adverse events include death, hospitalization, renal replacement therapy (dialysis or kidney transplantation), and acute suicidal intent during the first 8 weeks of the study.	Assessed at weeks 4, 6, and 8.
Secondary	Quick Inventory of Depressive Symptomatology-Clinician Rated scale (QIDS-C)	Assess the change from baseline in the QIDS-C total score in each of the intervention arms vs. the control arm during the second 8 weeks of the study when participants who did not respond to the treatment arms will be receiving combination therapy with BAT and bupropion.	Assessed at weeks 8, 12, and 16.
Secondary	High sensitivity C-reactive protein	Change from baseline to Week 8 in the plasma level of high sensitivity C-reactive protein (hsCRP) in the intervention groups vs. control.	Assessed at baseline and week 8
Secondary	Adherence to medications by Pill Count	The proportion of participants in each arm that are adherent to antidepressant medications (or placebo, prescribed in the setting of the clinical trial). Adherence will be defined as 80% or greater of study drug taken.	Assessed at weeks 4, 8, 12, and 16.
Secondary	Fatigue assessed by the Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) scale	Change from baseline in the FACIT-F scale in the intervention groups vs. control. The FACIT has 13 items, each on a Likert scale, with a score range of 0-52, and higher scores indicating a lower level of fatigue.	Assessed at baseline and weeks 4, 8, 12, and 16
Secondary	Sleep assessed by the Insomnia Severity Index (ISI)	Change from baseline in the Insomnia Severity Index (ISI) in the intervention groups vs. control. The ISI has 7 items that measure insomnia severity, with higher scores indicating more severe insomnia.	Assessed at baseline and weeks 4, 8, 12, and 16
Secondary	Overall functioning assessed by the Sheehan Disability Scale (SDS)	Change from baseline in the SDS in the intervention groups vs. control groups. The SDS assesses functional impairment in 3 domains: work, social life, and family, each evaluated on a 10-point visual analog scale, which are summed into a single dimensional measure of global functional impairment that ranges from 0 (unimpaired) to 30 (highly impaired).	Assessed at baseline and weeks 4, 8, 12, and 16